Gain Therapeutics is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of the underwriters’ overallotment option to purchase 545,454 additional shares of common stock, at a public offering price of $11.00 per share. The gross proceeds to Gain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gain, were...
BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price of $11.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on March 18, 2021 under the symbol “GANX.” The offering is expected to close on March 22, 2021 subject to customary closing conditions. The underwriters have a 30-day option to purchase up to an additional 545,454 shares of...
BETHESDA, Md., March 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Gain is offering 3,636,364 shares of its common stock. The initial public offering price is expected to be between $10.00 and $12.00 per share, before underwriting discounts and commissions. In addition, Gain expects to grant the underwriters a 30-day option to purchase up to an additional 545,454...
GAIN THERAPEUTICS INC.
4800 Hampden Ln, St 200
Bethesda, MD 20814,
Phone: +1 301 500 1556
LifeSci Advisors, LLC
1 International Place
Boston, MA 02110
Phone: +1 617-430-7576